Fact Source: Financial Supervisory Service DART / 2026-02-10
Disclosure Type: Major Management Matters Related to Investment Judgment
💡 3-Second Summary
Celltrion has obtained simultaneous approval for both Part 1 and Part 2 of its global Phase 3 clinical trial protocol amendment for ‘CT-P55’, a Cosentyx biosimilar, from the European Medicines Agency (EMA).
📊 1. [Summary of Key Disclosure Content and Major Figures]
- Confirmation Date: February 10, 2026 (The date the approval was verified via the Clinical Trial Information System, CTIS)
- Application and Approval Dates: Application submitted on October 27, 2025 / Approved on February 9, 2026 (Both on local time basis)
- Regulatory Authority: European Medicines Agency (EMA)
- Trial Title: A Randomized, Active-Controlled, Double-Blind, Phase 3 Clinical Trial to Compare the Efficacy and Safety of CT-P55 and Cosentyx in Patients with Moderate to Severe Plaque Psoriasis
- Clinical Trial Phase: Global Phase 3 Clinical Trial
- Target Disease (Indication): Plaque psoriasis
- Clinical Trial Registration Number: EU CT number: 2024-513348-27-00
- Trial Objective: To evaluate and compare the efficacy and safety between CT-P55 and the reference product Cosentyx to demonstrate biosimilarity
- Trial Design and Scale:
- Number of Subjects: 153 patients
- Trial Duration: 56 weeks
- Study Design: Randomized, active-controlled, double-blind
[European Regulations & General Cautions]
- Pursuant to revised European clinical trial regulations, the application and approval process is divided into Part 1 (assessment of trial design and research methodology) and Part 2 (assessment of clinical sites and implementation). A clinical trial can only proceed once Part 2 is officially approved. This disclosure captures the simultaneous clearance of both Part 1 and Part 2.
- Statistically, the probability of an investigational clinical drug successfully securing final marketing authorization as a commercial medicine is approximately 10%.
- Expected metrics may not be achieved during clinical stages, leaving open the possibility that the company may alter or abandon its commercialization roadmaps.
- This disclosure will be utilized in subsequent press releases and IR materials.
📈 2. [Expert Perspective: What This Disclosure Means for Investors]
This regulatory approval disclosure marks a tangible operational advancement, confirming that the development framework for Celltrion’s major biosimilar pipeline ‘CT-P55’ has successfully navigated stringent European regulatory criteria. Rather than a mere administrative filing, the fact that the EMA granted simultaneous approval for both the scientific methodology (Part 1) and operational infrastructure (Part 2) validates the structural integrity of the amended trial protocol, effectively mitigating localized regulatory risks.
Under the current European regulatory architecture, securing the Part 2 clearance is the mandatory operational threshold required to initiate actual patient dosing and active field testing. Consequently, this simultaneous approval ensures that the planned 56-week assessment period can begin without immediate bureaucratic delays. However, as explicitly detailed in the report’s risk disclosure, the historical success rate for any clinical compound transitioning to a fully authorized commercial product hovers around 10%. Since the filing does not specify the concrete operational reasons for amending the protocol, investors could prudently track the actual enrollment velocity and subsequent data readouts of the 153 subjects over the medium term rather than factoring in guaranteed commercial growth.
📝 Editor’s Comment (by K-STOCK Editor)
Celltrion’s CT-P55 development timeline has reached a smooth administrative milestone with this dual Part 1 and Part 2 protocol amendment approval from the EMA. By satisfying both the methodological and clinical site evaluations concurrently, the company has secured the immediate green light needed to deploy its field studies against Cosentyx in Europe. Nevertheless, market participants must maintain a balanced analytical view, given that the broader biopharmaceutical sector historically faces a low 10% final approval probability. As the disclosure remains silent on the exact technical modifications made to the protocol, observing the steady execution of the 56-week trial remains the most reliable analytical anchor.
📢 Disclaimer and Source Information
Source: This content was newly structured and written based on official data submitted to the Financial Supervisory Service’s electronic disclosure system (DART).
Investment Risk Notice: This content is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial responsibilities rest entirely with the investor.
Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.
🔥 Bulls vs Bears, drop your analysis in the comments!
